During its first-quarter earnings call, Regeneron disclosed two deaths linked to cytokine release syndrome in a trial of its bispecific candidate REGN1979, being developed for follicular lymphoma. "Regeneron suggested the higher CRS toxicity was likely due to a heightened immune response, and noted the CRS was also seen in conjunction with increased tumor response," SVB Leerink's Geoffrey Porges said.